HRAS Q61L

CI-VAR-00003570Explore in graph →NP_005334.1:p.Gln61LeuNM_005343.3:c.182A>TClinVar 376033 CIViC 854 rs121913233

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 3 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma1
HRAS Q61L	Everolimus + SelumetinibCombination	Predictive	D	Supports Sensitivity Response	3	submitted	EID1955 Inhibition of mTOR or combined inhibition of MEK and mTOR reduced cell growth in a synergistic manner. Cells transformed with mutant HRAS isoforms Q61L, Q61R and G12V demonstrated equal sensitivity to… (full text at CIViC) PMID 26544513 · Kiessling et al., 2015 · Open in CIViC	civic
Malignant Neoplasm1
HRAS Q61L OR HRAS Q61R OR HRAS G12V	Binimetinib + Everolimus + Mirdametinib + MTOR Kinase Inhibitor AZD8055 + SelumetinibSubstitutes	Predictive	D	Supports

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Skin Squamous Cell Carcinoma1
HRAS Q61L	Vemurafenib	Predictive	C	Supports Resistance	—	submitted	EID3848 In a retrospective study of 23 patients with BRAF V600 mutation (a known vemurafenib sensitizing mutation) that developed cutaneous squamous-cell carcinoma upon treatment with vemurafenib monotherapy,… (full text at CIViC) PMID 22256804 · Su et al., 2012 · Open in CIViC	civic